Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Remission · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ generalised onset Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Continuation of status requiring a different drug or general anaesthesia · patients with status epilepticus
Lorazepam IV probably leads to lower continuation of status requiring a different drug or general… compared with diazepam IV (moderate certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant generalised tonic‐clonic seizures
Add‐on lamotrigine may leads to higher 50% or greater reduction in seizure frequency compared with placebo (low certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes seizure freedom (i.e. total cessation of seizure activity) compared with placebo (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes treatment withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Time on allocated treatment (retention time) · people with focal or generalized seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
50% responder rate · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects requiring withdrawal/discontinuation of study medication · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
Clobazam showed no clear difference in adverse effects requiring withdrawal/discontinuation of study… compared with phenytoin (low certainty).
1 finding from 1 review
Retention [ · people with focal or generalized seizures
Clobazam showed no clear difference in retention at 12 months compared with carbamazepine (low certainty).
1 finding from 1 review
Seizure freedom · people with focal or generalized seizures
Clobazam showed no clear difference in seizure freedom at 4 weeks compared with carbamazepine (low certainty).
2 findings from 1 review